BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 08, 2007
 |  BioCentury  |  Strategy

The right structure

Cytokinetics Inc. could get $125 million from Amgen Inc. before the latter even touches CYTK's CK-1827452, a cardiac myosin activator that has completed two Phase I studies in heart failure. But what CYTK President Robert Blum likes most about the deal is the structure of the co-promotion rights.

AMGN (Thousand Oaks, Calif.) paid CYTK $75 million up front for an option to license CK-1827452, including $33 million in an equity purchase.

CYTK (South San Francisco, Calif.) will pay for a Phase IIa trial that it expects to begin in early 2007. But if AMGN likes what it sees, it will need to pay out another $50 million...

Read the full 534 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >